You have 9 free searches left this month | to do more

bortezomib

Bortezomib is a drug used to treat Multiple Myeloma, Lymphoma, Mantle Cell Lymphoma, and other conditions. Bortezomib is being actively studied in 121 studies and prior, has been studied in 319.

Top SponsorsTop SitesTop Investigators
National Cancer Institute (NCI)Mayo ClinicIrene Ghobrial, MD
M.D. Anderson Cancer CenterDana-Farber Cancer InstitutePaul G. Richardson, MD
Dana-Farber Cancer InstituteWashington University School of MedicineE. Steve Woodle
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
N
Active, not recruiting
  • Lymphoma, Mantle Cell
  • Mantle Cell Lymphoma
  • Rituximab (R)
  • +4 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center, 9000 Rockville Pi
2021-09-21
Sep 21, 2021
S
Recruiting
  • Antibody-mediated Rejection
  • Bortezomib
  • Tehran, Iran, Islamic Republic of
    SBMU
2022-01-27
Jan 27, 2022
E
Active, not recruiting
  • Multiple Myeloma
  • Rionero in Vulture, Potenza, Italy
    Irccs Crob
2022-03-24
Mar 24, 2022
H
Recruiting
  • Hematological Malignancy
  • Bortezomib
  • Detroit, Michigan
    Henry Ford hospital
2021-12-23
Dec 23, 2021
M
Active, not recruiting
  • Solid Tumor
  • Urethral Cancer
  • Bortezomib
  • +2 more
  • Houston, Texas
    University of Texas MD Anderson Cancer Center
2022-02-21
Feb 21, 2022
N
Completed
  • Lung Diseases, Interstitial
  • +2 more
  • Bortezomib
  • +2 more
  • Chicago, Illinois
    Northwestern University
2021-08-02
Aug 2, 2021
U
Completed
  • Hodgkin's Lymphoma
  • Lymphoma, Non-Hodgkin
  • Ann Arbor, Michigan
    University of Michgan Comprehensive Cancer Center
2021-12-03
Dec 3, 2021
H
Recruiting
  • Acute Lymphoblastic Leukemia, in Relapse
  • +2 more
  • Bortezomib
  • Mexico City, Mexico
    Hospital General de México "Dr. Eduardo Liceaga"
2022-01-02
Jan 2, 2022
C
Not yet recruiting
  • Multiple Myeloma
  • (no location specified)
2022-03-23
Mar 23, 2022
M
Recruiting
  • Recurrent Plasma Cell Myeloma
  • Refractory Plasma Cell Myeloma
  • Bortezomib
  • +2 more
  • Rochester, Minnesota
    Mayo Clinic in Rochester
2021-10-06
Oct 6, 2021
E
Completed
  • Multiple Myeloma
  • Bortezomib
  • +3 more
  • Atlanta, Georgia
    Emory University Winship Cancer Institute
2021-11-01
Nov 1, 2021
P
Recruiting
  • Amyloidosis; Systemic
  • Beijing, China
    Peking Union Medical College Hospital
2021-05-31
May 31, 2021
N
Completed
  • Chronic Myeloid Leukemia (CML)
  • +4 more
  • Bortezomib
  • NK cells
  • Bethesda, Maryland
    National Institutes of Health Clinical Center, 9000 Rockville Pi
2022-04-07
Apr 7, 2022
G
Active, not recruiting
  • Neuroblastoma Recurrent
  • Little Rock, Arkansas
  • +5 more
2022-02-16
Feb 16, 2022
D
Terminated
  • Waldenstrom's Macroglobulinemia
  • Boston, Massachusetts
    Dana-Farber Cancer Institute
2021-04-22
Apr 22, 2021
J
Completed
  • Acute Myelogenous Leukemia
  • Sacramento, California
    University of California Comprehensive Cancer Center
2021-02-04
Feb 4, 2021
C
Completed
  • Contiguous Stage II Mantle Cell Lymphoma
  • +5 more
  • bortezomib
  • +9 more
  • Duarte, California
  • +1 more
2022-01-12
Jan 12, 2022
D
Active, not recruiting
  • Multiple Myeloma
  • Bortezomib
  • +2 more
  • Denver, Colorado
  • +7 more
2022-02-11
Feb 11, 2022